EP4236932A4 - Abbauende verbindung in einem medikament - Google Patents

Abbauende verbindung in einem medikament Download PDF

Info

Publication number
EP4236932A4
EP4236932A4 EP21887770.2A EP21887770A EP4236932A4 EP 4236932 A4 EP4236932 A4 EP 4236932A4 EP 21887770 A EP21887770 A EP 21887770A EP 4236932 A4 EP4236932 A4 EP 4236932A4
Authority
EP
European Patent Office
Prior art keywords
drug
degradation compound
degradation
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP21887770.2A
Other languages
English (en)
French (fr)
Other versions
EP4236932A1 (de
EP4236932B1 (de
Inventor
Rhett Mead SCHIFFMAN
Bruce Alan FIRESTONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visus Therapeutics Inc
Original Assignee
Visus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI202130387T priority Critical patent/SI4236932T1/sl
Priority to EP26150395.7A priority patent/EP4736853A2/de
Priority to HRP20260130TT priority patent/HRP20260130T1/hr
Priority to MA62049A priority patent/MA62049B1/fr
Priority to SM20260119T priority patent/SMT202600119T1/it
Application filed by Visus Therapeutics Inc filed Critical Visus Therapeutics Inc
Priority to RS20260189A priority patent/RS67818B1/sr
Publication of EP4236932A1 publication Critical patent/EP4236932A1/de
Publication of EP4236932A4 publication Critical patent/EP4236932A4/de
Application granted granted Critical
Publication of EP4236932B1 publication Critical patent/EP4236932B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EP21887770.2A 2020-11-02 2021-11-02 Abbauende verbindung in einem medikament Active EP4236932B1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP26150395.7A EP4736853A2 (de) 2020-11-02 2021-11-02 Abbauende verbindung in einem medikament
HRP20260130TT HRP20260130T1 (hr) 2020-11-02 2021-11-02 Razgradni spoj u lijeku
MA62049A MA62049B1 (fr) 2020-11-02 2021-11-02 Composé de dégradation dans un médicament
SM20260119T SMT202600119T1 (it) 2020-11-02 2021-11-02 Composto di degradazione in un medicamento
SI202130387T SI4236932T1 (sl) 2020-11-02 2021-11-02 Razpadna spojina v zdravilu
RS20260189A RS67818B1 (sr) 2020-11-02 2021-11-02 Degradantno jedinjenje u leku

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063108720P 2020-11-02 2020-11-02
US202163162367P 2021-03-17 2021-03-17
US202163257024P 2021-10-18 2021-10-18
PCT/US2021/057720 WO2022094462A1 (en) 2020-11-02 2021-11-02 Degradant compound in a medicament

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP26150395.7A Division EP4736853A2 (de) 2020-11-02 2021-11-02 Abbauende verbindung in einem medikament

Publications (3)

Publication Number Publication Date
EP4236932A1 EP4236932A1 (de) 2023-09-06
EP4236932A4 true EP4236932A4 (de) 2024-10-09
EP4236932B1 EP4236932B1 (de) 2026-01-07

Family

ID=81383327

Family Applications (2)

Application Number Title Priority Date Filing Date
EP26150395.7A Pending EP4736853A2 (de) 2020-11-02 2021-11-02 Abbauende verbindung in einem medikament
EP21887770.2A Active EP4236932B1 (de) 2020-11-02 2021-11-02 Abbauende verbindung in einem medikament

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP26150395.7A Pending EP4736853A2 (de) 2020-11-02 2021-11-02 Abbauende verbindung in einem medikament

Country Status (22)

Country Link
US (2) US20230390284A1 (de)
EP (2) EP4736853A2 (de)
JP (1) JP2023548336A (de)
KR (1) KR20230104645A (de)
AU (1) AU2021369566A1 (de)
CA (1) CA3195784A1 (de)
CL (1) CL2023001258A1 (de)
CO (1) CO2023007133A2 (de)
CR (1) CR20230190A (de)
DK (1) DK4236932T3 (de)
ES (1) ES3061413T3 (de)
FI (1) FI4236932T3 (de)
HR (1) HRP20260130T1 (de)
LT (1) LT4236932T (de)
MA (1) MA62049B1 (de)
MX (1) MX2023005031A (de)
PT (1) PT4236932T (de)
RS (1) RS67818B1 (de)
SI (1) SI4236932T1 (de)
SM (1) SMT202600119T1 (de)
TW (1) TW202233170A (de)
WO (1) WO2022094462A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117571883B (zh) * 2024-01-15 2024-03-19 四川智强医药科技开发有限公司 一种酒石酸溴莫尼定滴眼液的质量检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252061A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980818B2 (en) * 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CN102770135A (zh) * 2010-01-21 2012-11-07 阿勒根公司 眼内压降低作用持续时间长的α-2肾上腺素能激动剂
AU2016280616B2 (en) * 2015-06-18 2020-10-22 Lenz Therapeutics Operations, Inc. Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
CN108883102A (zh) * 2016-03-17 2018-11-23 远视眼治疗有限责任公司 用于治疗远视眼的组合物和方法
MX2020005217A (es) * 2017-11-21 2020-11-24 Sydnexis Inc Composicion oftalmica y dispositivo de administracion de la misma.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252061A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects

Also Published As

Publication number Publication date
AU2021369566A9 (en) 2025-04-10
US20240100046A1 (en) 2024-03-28
RS67818B1 (sr) 2026-03-31
WO2022094462A1 (en) 2022-05-05
TW202233170A (zh) 2022-09-01
CL2023001258A1 (es) 2023-12-22
KR20230104645A (ko) 2023-07-10
LT4236932T (lt) 2026-03-25
MA62049B1 (fr) 2026-02-27
CA3195784A1 (en) 2022-05-05
US20230390284A1 (en) 2023-12-07
CO2023007133A2 (es) 2023-06-20
FI4236932T3 (fi) 2026-02-12
MX2023005031A (es) 2023-06-29
PT4236932T (pt) 2026-02-23
EP4236932A1 (de) 2023-09-06
CR20230190A (es) 2023-09-06
AU2021369566A1 (en) 2023-06-22
EP4736853A2 (de) 2026-05-06
ES3061413T3 (en) 2026-04-01
SMT202600119T1 (it) 2026-05-12
HRP20260130T1 (hr) 2026-03-27
EP4236932B1 (de) 2026-01-07
SI4236932T1 (sl) 2026-04-30
JP2023548336A (ja) 2023-11-16
DK4236932T3 (da) 2026-02-09

Similar Documents

Publication Publication Date Title
EP4114183C0 (de) Fungizide zusammensetzungen
EP4286378A4 (de) Pyrimidopyranverbindung
EP4086277A4 (de) Langwirkende glp-1-verbindung
EP3925284A4 (de) Mobilitätsverbesserung in einem verbundenen zustand
EP4293025A4 (de) 4-aminochinazolinverbindung
EP4186903A4 (de) Chinazolinverbindung
EP4066893A4 (de) Heterocyclische verbindung
EP2149550A4 (de) Stickstoffhaltige fünfgliedrige heterocyclische verbindung
EP3897643A4 (de) Organische verbindung
EP3682881A4 (de) Verbindung mit zyklischer struktur
EP3500719A4 (de) Abbaubare pumpe in einem schuh
EP4072554A4 (de) Organische verbindung
EP3898221A4 (de) Organische verbindung
EP4050009A4 (de) Kleinmolekülige verbindung
EP4129392A4 (de) Schnell auflösende mikronadel
JP1716382S (ja) シリンジポンプ
EP4253386A4 (de) Deuteriummodifizierte thienopyridonverbindung
EP2266983A4 (de) Nitrogenierte 5-gliedrige heterocyclische verbindung
EP4071137A4 (de) Neuartige pyrrolverbindung
EP4053094A4 (de) Organische verbindung und organisches lichtemittierendes element
EP4434969A4 (de) Anti-sars-cov-2-arzneimittel
EP4395987A4 (de) Filmgebundene infusion
JP1741167S (ja) ホイールローダ
EP4317604A4 (de) Bagger
EP4116299A4 (de) Heterocyclische verbindung

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20260130T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031165000

Ipc: A61K0009000000

Ref document number: 602021046148

Country of ref document: DE

A4 Supplementary search report drawn up and despatched

Effective date: 20240910

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/439 20060101ALI20240904BHEP

Ipc: A61K 31/4164 20060101ALI20240904BHEP

Ipc: A61K 31/165 20060101ALI20240904BHEP

Ipc: A61K 47/38 20060101ALI20240904BHEP

Ipc: A61K 31/498 20060101ALI20240904BHEP

Ipc: A61K 31/27 20060101ALI20240904BHEP

Ipc: A61K 9/00 20060101AFI20240904BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250618

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20251117

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260107

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021046148

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20260206

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 4236932

Country of ref document: PT

Date of ref document: 20260223

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20260213

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 62049

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: CH

Ref legal event code: R17

Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260304

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20260130

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3061413

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20260401

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20260400590

Country of ref document: GR

Effective date: 20260407

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E025671

Country of ref document: EE

Effective date: 20260313